Targeting nutrient use by childhood blood cancers
Looking at the molecular effects inside Acute Myeloid Leukaemia cells treated with a specific new drug and investigating if the drug can be combined with other standard treatments.
‘ALL’ about metabolism: repurposing drugs for acute lymphoblastic leukaemia
Examining whether a group of drugs called gliflozins could be used to treat T-ALL
Using next-generation gene technology to help children with blood cancers in low-income countries.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
How does T-cell acute lymphoblastic leukaemia go to the brain?
Identifying drivers of central nervous system involvement in T-cell acute lymphoblastic leukaemia
Developing personalised treatments for brain-directed chemotherapy in childhood acute lymphoblastic leukaemia
ALLTogether1 CSF-FLOW Study
Identifying the genetic changes in T-cell acute lymphoblastic leukaemia that fails to respond to chemotherapy
Deciphering the genomic landscape of childhood refractory t-cell acute lymphoblastic leukaemia
Advance testing efficacy of albendazole in childhood acute myeloid leukaemia
Investigating the preclinical efficacy of albendazole in paediatric acute myeloid leukaemia
Understanding a potentially new therapeutic target in incurable childhood acute lymphoblastic leukaemia
Dissecting the role of CD133/PROM1 in MLL rearranged acute lymphoblastic leukaemia to develop novel targeted therapy
Do errors in the production of antibody genes cause mutations that lead to leukaemias with poor survival rates?
The Role of Cut-and-Run, an Aberrant V(D)J Recombination Reaction, in the Development of Acute Lymphoblastic Leukaemias with Poor Prognosis